Last reviewed · How we verify
NCT06689462
Appraisal of the Modified Cancer Cachexia Index in Locally Advanced Gastric Cancer Patients Undergoing Neoadjuvant Chemotherapy
trial in Gastric Cancer in 600 participants. Completed in 13 July 2024.
30 June 2024
Quick facts
| Lead sponsor | Fujian Medical University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 1 December 2023 |
| Primary completion | 30 June 2024 |
| Estimated completion | 13 July 2024 |
| Sites | 1 location across China |
Conditions studied
- Gastric Cancer — all drugs for Gastric Cancer →
- Neoadjuvant Chemotherapy — all drugs for Neoadjuvant Chemotherapy →
- Computed Tomography — all drugs for Computed Tomography →
- Random Forest Model — all drugs for Random Forest Model →
Sponsor
Fujian Medical University
Who can join
Adults 18 to 84, any sex, with Gastric Cancer or Neoadjuvant Chemotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, consecutive 600 patients with LAGC(cT2-4NanyM0) who underwent NACT between Jan. 2010 and Jun. 2022 were identified from two tertiary hospitals. The mCXI was constructed based on Random Forest model, calculated as (post-NACT L3 subcutaneous adipose tissue area \[SAT\])×(post-NACT serum albumin \[ALB\])/(post-NACT platelet count \[PLT\]). Patients were categorized into two subgroups: mCXI-low and mCXI-high. mCXI is associated with the overall prognosis in patients with locally advanced gastric cancer underwent neoadjuvant chemotherapy, is superior to traditional CXI, and may serve as a decision-making tool for guiding personalized postoperative adjuvant chemotherapy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Development and validation of a novel modified cancer cachexia index in patients with locally advanced gastric cancer undergoing neoadjuvant chemotherapy: a multicenter cohort study.
Zhang LK, Zheng HL, Zheng XY, Xu BB, et al · · 2025 · cited 2× · PMID 40503786 · DOI 10.1097/js9.0000000000002707
Verify or expand the search:
- PubMed search for NCT06689462
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
Other Fujian Medical University trials
Trials by the same sponsor.
- NCT07314203 — Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastr · Phase 3 · not yet recruiting
- NCT07491263 — Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Le · Phase 1 · not yet recruiting
- NCT07275034 — A Virtual Reality-Based Horticultural Planting Program for Elderly With Subthreshold Depression · NA · not yet recruiting
- NCT07383909 — Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery · NA · recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06689462 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Medical University
- Last refreshed: 14 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06689462.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing